Sun Pharmaceutical Industries Ltd.

BSE: 524715 | NSE: SUNPHARMA
Large Cap | Pharmaceuticals & Drugs
1673.55
4.35 (0.26%)
< Home < Back

Sun Pharma’s US-based unit recalls 14,064 cartons of medication to treat erosive esophagitis

Date: 05-12-2022

Sun Pharmaceutical Industries’ US-based unit -- Sun Pharmaceutical Industries Inc is recalling 14,064 cartons of a medication to treat erosive esophagitis or heartburn caused by gastroesophageal reflux disease (GERD). The company is recalling the affected lot, produced at its Mohali plant, due to ‘discoloration’.

The company has commenced the Class II voluntary recall in the US on July 25, 2022. As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.